ReviewInternational journal of molecular medicine2026
Metabolic messengers from the gut to the joint: Toward precision management of osteoarthritis (Review).
Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis has evolved from a mechanical concept to a metabolic whole‑organ disease driven by systemic inflammation. The 'gut‑joint axis' represents a 'biological highway' where intestinal dysbiosis permits the translocation of microbial metabolites into synovial joints. This review focuses on three pivotal metabolite classes with opposing roles: Short‑chain fatty acids (SCFAs), which function as anti‑inflammatory guardians; trimethylamine N‑oxide (TMAO), which acts as a pro‑inflammatory aggressor; and bile acids (BAs), which serve as complex regulators that balance homeostasis and catabolism. This review further proposes a novel 'metabolite homeostasis imbalance' theoretical framework, which posits that osteoarthritis pathogenesis is driven by the disruption of the dynamic equilibrium between protective (SCFAs), destructive (TMAO) and context‑dependent regulatory (BAs) microbial metabolites. This integrative 'metabolite homeostasis imbalance' model deconstructs the 'biological highway' metaphor into a three‑tier mechanistic schema encompassing intestinal barrier integrity, systemic metabolite trafficking and tissue‑specific effector functions in the joint microenvironment, thereby providing a unifying conceptual foundation bridging scattered single‑metabolite research and mechanism‑targeted precision OA management. Additionally, the potential of sports medicine interventions, including exercise and probiotics, to modulate this axis is evaluated. This synthesis provides a comprehensive theoretical basis for novel clinical strategies targeting gut‑derived metabolic networks to preserve joint health and mitigate disease progression.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.